JP2009526087A - 悪液質の予防および処置のための組成物および方法 - Google Patents

悪液質の予防および処置のための組成物および方法 Download PDF

Info

Publication number
JP2009526087A
JP2009526087A JP2008555886A JP2008555886A JP2009526087A JP 2009526087 A JP2009526087 A JP 2009526087A JP 2008555886 A JP2008555886 A JP 2008555886A JP 2008555886 A JP2008555886 A JP 2008555886A JP 2009526087 A JP2009526087 A JP 2009526087A
Authority
JP
Japan
Prior art keywords
day
roxithromycin
agonist
macrolide
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2008555886A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009526087A5 (https=
Inventor
リチャード ケンリー，
ジョナス イクブロム，
ミハイル デニセンコ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2009526087A publication Critical patent/JP2009526087A/ja
Publication of JP2009526087A5 publication Critical patent/JP2009526087A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2008555886A 2005-12-22 2006-12-20 悪液質の予防および処置のための組成物および方法 Withdrawn JP2009526087A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75311805P 2005-12-22 2005-12-22
US77275206P 2006-02-13 2006-02-13
PCT/IB2006/004315 WO2008093148A2 (en) 2005-12-22 2006-12-20 Compositions and methods for prevention and treatment of cachexia

Publications (2)

Publication Number Publication Date
JP2009526087A true JP2009526087A (ja) 2009-07-16
JP2009526087A5 JP2009526087A5 (https=) 2010-01-07

Family

ID=38194678

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008555886A Withdrawn JP2009526087A (ja) 2005-12-22 2006-12-20 悪液質の予防および処置のための組成物および方法

Country Status (6)

Country Link
US (1) US8080528B2 (https=)
EP (1) EP1991270A4 (https=)
JP (1) JP2009526087A (https=)
MX (1) MX2008007790A (https=)
NO (1) NO20083240L (https=)
WO (1) WO2008093148A2 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE457169T1 (de) 1998-10-15 2010-02-15 Imp Innovations Ltd Verbindungen für die behandlung von gewichtsverlust
GB0624282D0 (en) * 2006-12-05 2007-01-10 Cavalla David Treatment of cachexia
EP2155180B1 (en) * 2007-04-24 2016-07-13 Acacia Pharma Limited Drug combination and its use in the treatment of muscle loss
US8404235B2 (en) 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US8178101B2 (en) 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
US7906117B2 (en) 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
US8252286B2 (en) 2007-05-21 2012-08-28 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
HUE032563T2 (en) 2007-05-21 2017-09-28 Alderbio Holdings Llc Antibodies to IL-6 and their use
US9701747B2 (en) 2007-05-21 2017-07-11 Alderbio Holdings Llc Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
WO2009064532A1 (en) * 2007-11-18 2009-05-22 Anaborex, Inc. Compositions and methods for treating serous exudative effusion
US8257684B2 (en) * 2008-03-26 2012-09-04 Neurosigma, Inc. Methods for identifying and targeting autonomic brain regions
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8337847B2 (en) 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
CA2744400C (en) * 2008-11-25 2019-01-15 Alder Biopharmaceuticals, Inc. Antibodies to il-6 and use thereof
WO2011066374A2 (en) 2009-11-24 2011-06-03 Alder Biopharmaceuticals, Inc. Antagonists of il-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
US8791105B2 (en) 2010-07-14 2014-07-29 Kansas State University Research Foundation Methods for alleviating chronic pain and improving performance of cattle undergoing dehorning or castration
US9304134B2 (en) 2010-11-23 2016-04-05 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of anemia
US20160009767A9 (en) * 2012-03-28 2016-01-14 Affibody Ab Oral administration
WO2020018554A1 (en) * 2018-07-17 2020-01-23 The Regents Of The University Of California Methods of treating renal disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859782A (en) * 1986-06-26 1989-08-22 Harbor Branch Oceanographic Institution, Inc. Misakinolide compositions and their derivatives
EP0308157B1 (en) * 1987-09-15 1997-02-26 The Rowett Research Institute Therapeutic applications of beta-adrenergic agonists
HUT50044A (en) * 1988-04-12 1989-12-28 Bristol Myers Co Process for producing pharmaceutical composition comprising megestrol acetate as active ingredient
US5252564A (en) * 1991-03-29 1993-10-12 The United States Of America As Represented By The Secretary Of Agriculture Method to decrease cortisol secretion by feeding melengesterol acetate
EP0771205A2 (de) * 1994-06-28 1997-05-07 Dr. Zerle Gmbh Neue klinische anwendungen von polyen-makroliden
US5750493A (en) * 1995-08-30 1998-05-12 Raymond F. Schinazi Method to improve the biological and antiviral activity of protease inhibitors
US6706892B1 (en) * 1999-09-07 2004-03-16 Conjuchem, Inc. Pulmonary delivery for bioconjugation
US7101576B2 (en) * 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
US7211568B2 (en) * 2003-12-18 2007-05-01 Kosan Biosciences Incorporated 9-Desoxoerythromycin compounds as prokinetic agents
WO2008004224A2 (en) 2006-07-03 2008-01-10 Arie Levine Synergistic compositions for crohn's disease and inflammatory gastrointestinal disorders

Also Published As

Publication number Publication date
EP1991270A2 (en) 2008-11-19
WO2008093148A3 (en) 2009-04-16
WO2008093148A2 (en) 2008-08-07
MX2008007790A (es) 2009-03-04
EP1991270A4 (en) 2009-12-02
US20070149465A1 (en) 2007-06-28
NO20083240L (no) 2008-09-22
US8080528B2 (en) 2011-12-20

Similar Documents

Publication Publication Date Title
US8080528B2 (en) Compositions and methods for treatment of cachexia
WO2007095497A2 (en) Compositions and methods for prevention and treatment of cachexia
US12527807B2 (en) Drug composition containing abiraterone acetate, and preparation method therefor and application thereof
TWI874339B (zh) 用於治療先天性腎上腺增生之crf1受體拮抗劑、醫藥配方及其固體形式
US20190125765A1 (en) Combination therapies and methods of use thereof for treating cancer
JP5490354B2 (ja) フェノフィブレート含有医薬組成物およびその製造方法
CN116096373A (zh) 用于治疗先天性肾上腺增生症的crf1受体拮抗剂
WO2008122190A1 (en) The composition comprising l-carnitine or derivatives thereof and its use
JP2017210476A (ja) 少なくとも１つの炎症性要素を呈する腸管疾患を治療するための方法
MX2008007786A (es) Dispositivo para convertir energia termica en energia electrica.
RU2586742C2 (ru) Композиция для лечения метаболических расстройств
JP6371379B2 (ja) ヒドロコルチゾンを含有する組成物
JP2017200942A (ja) 副腎機能障害の治療
TW200840590A (en) Compositions and methods for prevention and treatment of cachexia
EP3908260B1 (en) Pharmaceutical composition for reducing protein bound uremic toxins
CN120022301B (zh) 镰刀菌在制备预防或治疗代谢功能障碍或其相关并发症的药物中的应用
JP7532328B2 (ja) 先天性副腎過形成を処置するためのｃｒｆ１受容体アンタゴニスト、その医薬製剤および固体形態
US20210205333A1 (en) Methods and compositions for treating 25-hydroxyvitamin d deficiency
HK40073040B (en) Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia
CN121568697A (zh) 十二烷酸睾酮酯组合物和方法
JPH04159226A (ja) 血中脂質低下剤
HK40005336B (zh) 包含美金刚和褪黑素的组合的药物组合物
HK1084895B (en) Pharmaceutical composition containing fenofibrate and method for the preparation thereof

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20090605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20090605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091110

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091110

A072 Dismissal of procedure [no reply to invitation to correct request for examination]

Free format text: JAPANESE INTERMEDIATE CODE: A073

Effective date: 20110315

A300 Application deemed to be withdrawn because no request for examination was validly filed

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20110405